We are a clinical-stage biotechnology company that seeks to discover, develop and commercialize novel therapies capable of transforming treatment paradigms in the management of serious medical conditions.

We are currently exploring strategic alternatives, which may include: an acquisition of another company; acquisitions or in-licensing of products or product candidates, technologies or other assets; the sale of all or substantially all of the assets of Edge; a strategic merger or other business combination transaction; or another transaction between Edge and a third party.